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SUMMARY
Synthetic lethality triggered by PARP inhibitor (PARPi) yields promising therapeutic results. Unfortunately,
tumor cells acquire PARPi resistance, which is usually associated with the restoration of homologous recom-
bination, loss of PARP1 expression, and/or loss of DNA double-strand break (DSB) end resection regulation.
Here, we identify a constitutive mechanism of resistance to PARPi. We report that the bone marrow micro-
environment (BMM) facilitates DSB repair activity in leukemia cells to protect them against PARPi-mediated
synthetic lethality. This effect depends on the hypoxia-induced overexpression of transforming growth factor
beta receptor (TGFbR) kinase on malignant cells, which is activated by bone marrow stromal cells-derived
transforming growth factor beta 1 (TGF-b1). Genetic and/or pharmacological targeting of the TGF-b1-TGFbR
kinase axis results in the restoration of the sensitivity of malignant cells to PARPi in BMM and prolongs the
survival of leukemia-bearing mice. Our finding may lead to the therapeutic application of the TGFbR inhibitor
in patients receiving PARPis.
INTRODUCTION
Oncogenic tyrosine kinases (OTKs) are found in many types of
tumors, including hematologic malignancies (Blume-Jensen
and Hunter, 2001; Scheijen and Griffin, 2002). For example, acti-
vating mutations of FLT3 cell membrane tyrosine kinase (e.g.,
FLT3[ITD/TKD]), of ABL1 cytoplasmic/nuclear tyrosine kinase
(e.g., BCR-ABL1), and of JAK2 cytoplasmic tyrosine kinase
(e.g., JAK2[V617F]) play a pathogenic role in acute myeloid leu-
kemias (AMLs), chronic myeloid leukemia (CML), and myelopro-
liferative neoplasms (MPNs), respectively. The standard treat-
ment for these malignancies typically uses selective tyrosine
kinase inhibitor (TKis) such as quizartinib for FLT3(ITD/TKD) (Lar-
rosa-Garcia and Baer, 2017), imatinib for BCR-ABL1 (Khorashad
and Deininger, 2011), and ruxolitinib for JAK2(V617F) (Passa-
monti and Maffioli, 2018), and/or chemotherapy (cytosine arabi-
noside in combination with anthracyclines). However, with the
exception of CML in chronic phase (CML-CP), complete remis-
sions are rare, and after the initial response, the diseases invari-
ably progress, often becoming more malignant (Shimada, 2019).
In addition, a subset of CML-CP patients does not respond
favorably to TKi, eventually experiencing progression to a fatal
blast phase CML (CML-BP) (Perrotti et al., 2010). Therefore,
there is a clear need for additional therapies to improve thera-
peutic outcomes in patients with OTK-driven leukemias.
Previous reports (Chen et al., 2014; Marty et al., 2013; Sallmyr
et al., 2008), including our own (Bolton-Gillespie et al., 2013;Mai-
frede et al., 2018; Nieborowska-Skorska et al., 2012, 2017a)
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indicated that the OTK+ malignant cells accumulate high
numbers of spontaneous and drug-induced DNA double-strand
breaks (DSBs) in comparison to normal cells, but theymanage to
survive because of their enhanced/altered ability to repair these
breaks. DSBs, the most lethal DNA lesions, are repaired by two
major mechanisms, homologous recombination (HR; key
effector proteins: BRCA1, BRCA2, CtIP, and RAD51) and DNA-
protein kinase (DNA-PK)-mediated non-homologous end-joining
(D-NHEJ; key effector proteins: 53BP1, DNA-PKcs, KU70,
KU80, and LIG4) (Figure S1) (Chapman et al., 2012). Both HR
and D-NHEJ repair DSBs in proliferating cells, while D-NHEJ
plays a major role in quiescent cells. Poly (ADP-ribose) polymer-
ase 1 (PARP1)-dependent alternative NHEJ (Alt-NHEJ; key
effector proteins: PARP1 and LIG3) serves as backup in both
proliferating and quiescent cells (Feng et al., 2011; Karanam
et al., 2012). The existence of these redundant pathways creates
the opportunity to use a phenomenon called ‘‘synthetic
lethality,’’ which was originally applied to eliminate cancer cells
with mutations in BRCA1 and BRCA2 by PARP inhibitor (PARPi)
(Bryant et al., 2005; Farmer et al., 2005; Yap et al., 2011).
Although BRCA1/2mutations are rare in hematological malig-
nancies (Roy et al., 2011), we and other researchers identified
myeloid and lymphoid malignancies displaying specific defects
in DSB repair, which are susceptible to synthetic lethality trig-
gered by PARPi (Cimmino et al., 2017; Esposito et al., 2015;
Maifrede et al., 2017, 2018; Molenaar et al., 2018; Nieborow-
ska-Skorska et al., 2017a, 2017b; Piao et al., 2017; Podszywa-
low-Bartnicka et al., 2014; Tobin et al., 2013). In addition, we
discovered that the TKi-mediated inhibition of FLT3(ITD/TKD),
JAK2(V617F), and BCR-ABL1 kinases caused the downregula-
tion of key effectors of HR (BRCA1, BRCA2, PALB2 and/or
RAD51) and D-NHEJ (LIG4) associated with inhibition of HR
and D-NHEJ activities and, consequently, sensitized prolifer-
ating and quiescent malignant hematopoietic cells to PARPi-
mediated synthetic lethality (Maifrede et al., 2018; Nieborow-
ska-Skorska et al., 2017a, 2017b; Sullivan-Reed et al., 2018).
These observations resulted in clinical trials that tested PARPi
in patients with hematological malignancies (reviewed in Faraoni
et al., 2019).
Since these malignancies usually reside in peripheral blood
(PB) and hematopoietic tissues (e.g., bone marrow [BM],
spleen), it is of paramount importance to test the effect of
PARPi in different microenvironments, especially because
the BM microenvironment (BMM) protects leukemia cells
against TKi and cytotoxic drugs (Zhou et al., 2016). This effect
is associated with the leukemia-mediated remodeling of
BMM, which engages various cells and cytokines (e.g., C-X-
C motif chemokine 12 [CXCL12] - C-X-C chemokine receptor
type 4 [CXCR4] pathway and transforming growth factor beta
1 [TGF-b1] - transforming growth factor beta receptor (TGFbR)
kinase signaling) (Brunen et al., 2013; Schelker et al., 2018;
Zeng et al., 2009).
We report here that HR and/or D-NHEJ-deficient hematologi-
cal malignancies, which are sensitive to PARPi-mediated syn-
thetic lethality in conditions mimicking the PB microenvironment
(PBM), are resistant to PARPi in conditions mimicking the BMM.
We show that TGF-b1 produced by BM stromal cells activates a
hypoxia-induced TGFbR kinase-SMAD2/3 pathway in leukemic
cells to promote DSB repair. Genetic and pharmacological inhi-
bition of TGFbR kinase and SMAD3 reduced DSB repair and
restored the sensitivity of leukemic cells to PARPi in the BMM,
suggesting potential clinical applications of TGFbR kinase inhib-
itors in PARPi-mediated therapies.
RESULTS
BMM Protects Hematological Malignant Cells against
PARPis
To test the impact of the BMM on PARPi-mediated synthetic
lethality, previously identified BRCA1/2 pathway-deficient leuke-
mias (e.g., BCR-ABL1 BRCA1-deficient CML, AML1-
ETOBRCA2-deficient AMLs, and BRCA1/2-deficient AMLs; Es-
posito et al., 2015; Nieborowska-Skorska et al., 2017b; Podszy-
walow-Bartnicka et al., 2014), and FLT3(ITD);TET2mut AMLs
and JAK2(V617F);TET2mut MPNs (TET2mut was associated
with BRCA1 deficiency and enhanced sensitivity to DNA-
damaging agents; Chen et al., 2018) were incubated in condi-
tions mimicking the BMM and PBM with PARPi olaparib and ta-
lazoparib (Figure 1A). Autologous and allogeneic BM stromal
cells and stromal cell-derived cell lines (human HS-5 and murine
OP9) were used to create stromal monolayers, as indicated.
The results of clonogenic tests clearly showed that when
compared to the PBM, the BMM-dc protected human and mu-
rine malignant cells from the toxic effect of PARPi, whereas
normal cells were resistant to PARPi in both the PBM and
BMM (Figures 1B and 1C). Since the protective effect of the
BMM was sustained when human and murine malignant cells
were separated from stroma cells by 0.4 mm polyethylene tere-
phthalate (PET) cell culture insert (BMM-idc) and was also
observed using stromal cell conditioned medium (BMM-cm),
we concluded that cell-cell contact and extracellular vesicles
were not involved (Figure 1D). Moreover, BMM-direct contact
(dc) also protected LinCD34+CD38-CFSEmax quiescent malig-
nant hematopoietic stem cells from the toxic effect of PARPi ola-
parib in a malignant cell-stromal cell contact-independent
manner (Figure 1E).
TGF-b1-TGFbR Signaling in the BMM Causes
Resistance to PARPis
The results in Figure 1 implicated cytokine-dependent resistance
to PARPi in the BMM. Hematologic malignancies induce exten-
sive ‘‘remodeling’’ of the BM niche, which involves numerous cy-
tokines, including CXCL12 and TGF-b1 (Schepers et al., 2015;
Tabe and Konopleva, 2017).
TGFbR1 inhibitor SB431542 and TGF-b1 neutralizing antibody
1D11 sensitized human FLT3(ITD);TET2mut and/or murine
FLT3(ITD);Tet2/ leukemia cells to PARPi olaparib and TKi qui-
zartinib in BMM (Figure S2). However, inhibitors of the CXCL12-
CXCR4 pathway (CXCR4i AMD3100 and CXCR4 antagonist
WZ811) sensitized leukemia cells to quizartinib, but they did
not affect the response to olaparib. Therefore, these results sug-
gest the key role of the TGF-b1-TGFbRpathway in the resistance
to PARPi in the BMM.
TGF-b1, a major cytokine involved in the leukemic BM niche
remodeling process, is produced by BM stromal cells (Duan
et al., 2014; Krause et al., 2013). We confirmed that TGF-b1




was secreted by stromal cells (primary stromal cells and cell lines
HS-5 and OP9) in our experimental conditions (Figure S3). TGF-
b1-induced oligomerization of TGFbR1 and TGFbR2 subunits
causes the activation of TGFbR serine/threonine kinase activity,
followed by the phosphorylation of downstream targets—for
example, SMAD2 and SMAD3—which oligomerize with
SMAD4 to modulate the transcription of the target genes (Heldin
and Moustakas, 2016). By using flow cytometry and western
analysis we detected a 2- to 3-fold increase in TGFbR1 and
TGFbR2 expression in human FLT3(ITD);TET2mut LinCD34+
primary AML cells and in BCR-ABL1 K562 cells in BMM-dc
versus PBM (Figure 2A). This effect was triggered by hypoxia
(Figure 2B) and was associated with the enhanced phosphoryla-
tion of SMAD2 and SMAD3 (Figure 2C). However, we did not
detect an elevated DNA damage response (no increase in phos-
pho-ATM and g-H2AX was observed), as reported in epithelial
cells (Li et al., 2019).
To obtain direct evidence that TGF-b1 / TGFbR
signaling regulates sensitivity to PARPi in the BMM, TGFbR2
was deleted by tamoxifen-inducible Cre endonuclease in
JAK2(V617F);Tgfbr2/ murine MPN-like cells (Figure 2D, right
panels) or downregulated by CRISPR-Cas9 in BCR-ABL1
K562-Cr cells (Figure 2E, inset). Furthermore, TGF-b1 synthesis
was reduced by CRISPR-Cas9 in the HS-5-Cr stromal cell line
Figure 1. BMM Protects BRCA-Deficient Leukemia Cells from PARPi-Mediated Toxicity
(A) Experimental scheme. PBM, peripheral blood microenvironment mimicking conditions; BMM, bone marrow microenvironment mimicking conditions, dc,
direct contact; idc, indirect contact; cm, conditioned medium.
(B and C) Clonogenic activity of LinCD34+ human (h) and LincKit+ murine (m) malignant hematopoietic cells expressing indicated oncogenes (n = 3–4 donors
[patients or mice]/group) and normal human hematopoietic cells (n = 3 healthy donors) after treatment with olaparib (B) or talazoparib (C) in PBM (white circles)
and BMM-dc (black circles); stromal cells are indicated.
(D and E) LinCD34+ human and LincKit+ murine malignant hematopoietic cells expressing indicated oncogenes were treated with olaparib in PBM, BMM-dc,
BMM-idc, and in BMM-cm; stromal cells are indicated in (B). Results represent mean % ± SDs of (D) colonies and (E) LinCD34+CD38CFSEmax quiescent cells
(when compared to untreated cells); *p < 0.05 when compared to PBM.




(Figure 2F, left panel inset). The results in Figures 2D–2F clearly
show that the deletion of TGFbR2 in hematopoietic malignant
cells or the inhibition of TGF-b1 production by stromal cells
was associated with the enhanced sensitivity of malignant cells
to PARPi olaparib in BMM-dc. In addition, the absence of
PARP1 in FLT3(ITD);Tet2/;Parp1// cells strongly sensitized
them to TGFbR1i SB431542 in the BMM-dc (Figure 2G).
Conversely, stimulation of the TGFbR kinase pathway by recom-
binant TGF-b1 in human LinCD34+ FLT3(ITD);TET2mut cells
and murine Linc-Kit+ FLT3(ITD);Tet2/ cells in hypoxia (as
documented by the enhanced phosphorylation of SMAD2 and
SMAD3) induced resistance to olaparib (Figure 2H). These re-
sults strongly suggest that the hypoxia-induced overexpression
of TGFbR1/2 kinase sensitizes malignant hematopoietic cells to
stromal cells-derived TGF-b1 to induce resistance to PARPi in
BMM.
Figure 2. TGF-b1 - TGFbR Kinase Signaling Induced Resistance to PARPi in the BMM
(A and B) TGFbR1 and TGFbR2 expression in human FLT3(ITD);TET2mut LinCD34+ AML cells (3 patients) and in BCR-ABL1 K562 cells was detected by flow
cytometry (diagrams) and by western blot (insets) in (A) PBM (white histograms), BMM-dc (black histograms), and in (B) PBM (white histogram), BMC-idc (dark
gray histogram), and PBM + hypoxia (light gray histogram).
(C) Western blots detected indicated proteins in nuclear lysates from human FLT3(ITD);TET2mut LinCD34+ cells in PBM and BMM-dc.
(D) Sensitivity of JAK2(V617F);Tgfbr2/ and JAK2(V617F);Tgfbr2+/+ cells to 1 mM olaparib in BMM-dc. Results represent mean % colonies ± SDs when
compared to untreated cells; *p < 0.05. Depletion of Tgfbr2 in tamoxifen (Tmx)-treated cells and expression of JAK2(V617F) in Tmx-untreated (–) and -treated (+)
cells were validated by immunofluorescence (upper and lower right panels, respectively).
(E) Sensitivity of BCR-ABL1 K562-WT (wild-type) and K562-Cr cells to olaparib in BMM-dc. The results represent mean % colonies ± SDs when compared to
untreated cells.
(F) Sensitivity of K562-wt and Kasumi-1 cells to olaparib when cultured in BMM-dc with HS-5 cells and HS-5-Cr cells with the downregulated production of TGF-
b1 (inset, left panel). The results represent mean % colonies ± SDs.
(G) LincKit+ murine FLT3(ITD);Tet2/ (FT) and FLT3(ITD);Tet2/;Parp1/ (FTP) cells were treated with the indicated concentrations of SB431542 in BMM-dc
conditions followed by plating in methylcellulose. The results represent mean % colonies ± SDs.
(H) Human LinCD34+ FLT3(ITD);TET2mut AML cells and murine Linc-Kit+ FLT3(ITD);Tet2/ cells in hypoxia were treated with 1 mMolaparib in the presence of
3 ng/mL recombinant human TGF-b1 (rhTGF-b1) or recombinant mouse (rmTGF-b1), respectively, (yellow bars) or vehicle (gray bars), or were cultured in nor-
moxia (white bars). The results represent mean%colonies ±SDs; *p < 0.05.Western blots of phospho-SMAD2 (pSMAD2) and SMAD2, and pSMAD3 and SMAD3
in representative nuclear lysates from cells treated with TGF-b1 or vehicle.
See also Figures S2 and S3.




Figure 3. Inhibition of TGF-b1-TGFbR Kinase Signaling Restored the Sensitivity of OTK-positive Cells to TKi+PARPi in the BMM.
(A) Human LinCD34+ primary FLT3(ITD);TET2mut AML cells (3 patients) and JAK2(V617F);TET2mutMPN cells (1 patient), and BCR-ABL1 CML K562 cells were
left untreated or were treated with 2.5 mM olaparib (O), 50 nM quizartinib (Q), 25 nM ruxolitinib (R), 1 mM imatinib (I), O + Q, O + R, and O + I in PBM (transparent
bars) or BMM-dc (filled bars, stromal cells indicated) in the presence of 10 mM SB431542 or vehicle, as indicated. The results represent mean% colonies ± SDs;
*p < 0.05 when compared to corresponding black bars. Western blots show pSMAD2 and total SMAD2 in nuclear lysates.
(B) Sensitivity of FLT3(ITD) MV-4-11 AML cells to 50 nM talazoparib + 100 nM quizartinib in the presence of 25 mMSB431542 (orange bar) or vehicle (black bar) in
BMM-3d co-culture. The results represent mean relative luminescence units (RLUs) to protein absorbance in the sample ± SD. Upper image, a sphere image
taken using bright-field microscope Motic AE20 with objective 43. Lower image, overlay of bright field and GFP fluorescence (GFP+ cells in green) taken with a
Nikon Eclipse Ti microscope with objective 103.
(C) Clonogenic activity of LinCD34+ BM cells from healthy donors (hBMC, 3 donors) treated in BMM-dcwith 50 nM quizartinib (Q), 2.5 mMolaparib (O), and Q +O
in the presence of 10 mM SB431542 (orange bars) or vehicle (black bars). The results represent mean % colonies ± SDs.
(D) LincKit+murine FLT3(ITD);Tet2/AML-like cells (3 mice) were treated in BMM-dcwith 100 nMquizartinib (Q), 1 mMolaparib (O), andQ +O in the presence of
10 mM SB431542 (orange bars), 3 ng/mL 1D11 antibody (yellow bars), 10 mM galunisertib (brown bars), or vehicle (black bars). The results represent mean %
colonies ± SDs; *p < 0.05 when compared to corresponding vehicle-treated cells. Representative western blots of pSMAD3 and SMAD3 in nuclear lysates from
cells treated with SB431542, 1D11 antibody, galunisertib, or vehicle.
(legend continued on next page)




Inhibition of TGFbR Kinase Sensitizes Malignant
Hematopoietic Cells to PARPi in the BMM
We reported previously that quizartinib-treated FLT3(ITD) cells,
ruxolitinib-treated JAK2(V617F) cells, and imatinib-treated
BCR-ABL1 cells display ‘‘acute’’ deficiencies in HR and D-
NHEJ and were highly sensitive to PARPi-triggered synthetic
lethality (Maifrede et al., 2018; Nieborowska-Skorska et al.,
2017a, 2017b). In concordance, the combination of TKi (quizar-
tinib, ruxolitinib, imatinib) with PARPi olaparib inhibited the clo-
nogenic activity of human LinCD34+ FLT3(ITD);TET2mut AML
cells, JAK2(V617F);TET2mut MPN cells, and BCR-ABL1 CML
K562 cells in the PBM, and TGFbRi SB431542 did not alter this
effect (Figure 3A). However, in the BMM-dc, cells were resistant
to PARPi ± TKi, but the inhibition of TGFbR1 kinase by SB431542
(confirmed by the downregulation of phospho-SMAD2) restored
the sensitivity. SB431542 also sensitized FLT3(ITD) MV4-11 AML
cells to quizartinib + talazoparib in 3-dimensional BMM co-cul-
ture (BMM-3d) with HS-5 cells (Figure 3B). Importantly,
SB431542 did not enhance the sensitivity of LinCD34+ hemato-
poietic cells from healthy donors to TKi + PARPi in the BMM-dc
(Figure 3C).
Moreover, another TGFbR1i, galunisertib, as well as the TGF-
b1 neutralizing antibody 1D11 also restored the sensitivity of mu-
rine FLT3(ITD);Tet2/ leukemia cells to olaparib ± quizartinib in
BMM-dc (Figure 3D). In addition, we showed that not only stro-
mal cell lines but also autologous stromal cells protected murine
and human FLT3(ITD);Tet2/, FLT3(ITD);AML1-ETO, and BCR-
ABL1 leukemias against olaparib ± TKi in BMM-dc, and that
SB431542 and galunisertib eradicated the protective effect of
autologous stroma (Figure 3E).
In concordance with previous reports (Karantanou et al.,
2018), the BMM promoted the quiescence of leukemia cells
manifested by the accumulation of cells in G0/G1 phase of the
cell cycle (Figure S4). Quiescent leukemia stem cells (LSCs)
are refractory to TKis and are often responsible for the resistance
to therapies and/or disease relapse (Barnes and Melo, 2006; Li
and Bhatia, 2011).We demonstrated that the BMM-dc protected
FLT3(ITD);TET2mut LinCD34+CD38CFSEmax quiescent hu-
man AML stem cells against olaparib + quizartinib (Figure 3F).
Remarkably, quiescent AML stem cells treated with SB431542
re-gained the sensitivity to the combination of these drugs.
TGFbRi Enhances the Anti-Leukemia Effect of PARPi +
TKi In Vivo
The results presented in Figure 3 imply that TGFbRi should
enhance the elimination of leukemia cells from the BM of TKi +
PARPi-treated patients. To test this hypothesis, the anti-leuke-
mia effect of TKi (imatinib for BCR-ABL1 and quizartinib for
FLT3(ITD) cells) + PARPi (talazoparib) ± TGFbR1i (SB431542)
was examined in SCID mice bearing GFP+ BCR-ABL1 CML-
like andGFP+ FLT3(ITD);Tet2/ AML-like leukemias (Figure 4A).
A short and aggressive 7-day regimen was applied to test the
beneficial effects of TGFbRi. SCID mice were used as hosts to
exclude the impact of PARPi-mediated immune modulation on
the therapeutic effect (Césaire et al., 2018). Talazoparib was
used here because it displays better pharmacokinetic parame-
ters in mice than does olaparib (Shen et al., 2013) and was
already tested in mice against HR/D-NHEJ-deficient hematolog-
ical malignancies (Maifrede et al., 2018; Nieborowska-Skorska
et al., 2017a, 2017b).
As expected, imatinib + talazoparib and quizartinib + talazo-
parib exerted anti-leukemia effects in the PB of mice bearing
CML-like and AML-like leukemias, respectively, and the addition
of SB431542 did not enhance this effect (Figure 4B). Remark-
ably, while the anti-leukemia effects of the TKi + PARPi combina-
tion were quite limited in the BM and spleen, the addition of
TGFbRi greatly enhanced this effect. Moreover, TGFbRi pro-
longed the survival of CML-like and AML-like bearing mice
treated with TKi + PARPi (Figure 4C). Importantly, secondary re-
cipients of BM cells harvested at the end of the TKi + PARPi +
TGFbRi treatment survived longer than mice injected with cells
from TKi + PARPi-treated animals (Figure 4D), suggesting that
the addition of TGFbRi to TKi + PARPi targeted LSCs in the
BMniche. Immunohistochemical analysis of GFP+ leukemic cells
in BM supports the conclusion that TGFbRi enhanced the target-
ing of CML-like (Figure 4E) and AML-like (Figure 4F) leukemia
cells by TKi + PARPi in the BMM.
Inhibition of TGFbR Kinase Induces DSB Repair Defects
in Leukemia Cells in the BMM
We observed that the inhibition of the TGFbR kinase by
SB431542 was associated with the accumulation of DSBs (de-
tected by neutral comet assay) in olaparib and olaparib + quizar-
tinib-treated FLT3(ITD);Tet2/ murine AML-like cells in BMM-
dc (Figure 5A), which coincided with the enhanced sensitivity
to PARPi (Figures 2 and 3). However, the measurement of
DSBs by the detection of histone 2AX phosphorylated on serine
139 (g-H2AX) (Bonner et al., 2008) showed less abundant stain-
ing in olaparib + quizartinib-treated FLT3(ITD);Tet2/ cells when
TGFbR kinase was inhibited by SB431542 (Figure 5B). These re-
sults suggest that the ATM and/or ATR kinases-mediated
sensing of DSBs may be deregulated upon the inhibition of
TGFbR kinase (Bonner et al., 2008).
The impact of TGFbRi onDSB repair (Figure S1) was tested us-
ing specific reporter cassettes measuring HR, D-NHEJ, and Alt-
NHEJ repair activities (Figure 5C, right panel), as described
before (Nieborowska-Skorska et al., 2017b). The treatment
with SB431542 caused 9- and 2-fold reductions of HR and
(E) LinCD34+ cells from FLT3(ITD);AML1-ETO AMLs (3 patients), and Lin-cKit+ cells from FLT3(ITD);Tet2/ AML-like mice (3 mice) and BCR-ABL1 CML-like
mice (3mice) were treated in BMM-dcwith 100 nMquizartinib (Q), 1 mM imatinib (I), 1 mMolaparib (O), O + I, and O+Q in the presence of 10 mMSB431542 (orange
bars), 10 mMgalunisetrib (brown bars), or vehicle (black bars). The results represent mean% colonies ± SDs; *p < 0.05 when compared to corresponding vehicle-
treated cells.
(F) LinCD34+ cells from FLT3(ITD);TET2mut AML were treated in BMM-dc with 10 nM quizartinib (Q), 1 mM olaparib (O), and O + Q in the presence of 10 mM
SB431542 (orange bars) or vehicle (black bars). The results represent the mean number of LinCD34+CD38CFSEmax quiescent cells/5 3 105 cells ± SD; *p <
0.05 when compared to corresponding vehicle-treated cells.
See also Figure S4.
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D-NHEJ, respectively, whereas Alt-NHEJ was enhanced by 2-
fold (Figure 5C, left panel). Western blot analysis revealed that
TGFbRi-mediated modulation of DSB repair was associated
with the downregulation of ATM kinase (Figure 5D). In addition,
BRCA1 and BRCA2 (HR proteins) and DNA-PKcs and LIG4
(D-NHEJ) proteins were strongly downregulated in
FLT3(ITD);Tet2/ AML-like cells in BMM-dc after the inhibition
of TGFbR kinase. At the same time, TGFbRi did not affect the
expression of Alt-NHEJ proteins (PARP1, LIG3). These
TGFbRi-induced changes in DNA damage/repair were not
dependent on the cell cycle (Figure S5). ATM, BRCA1, BRCA2,
DNA-PKcs, and LIG4 but not Alt-NHEJ proteins were also down-
regulated in the CML K562-Cr cell line (in which expression of
TGFbR2 was reduced by CRISPR-Cas9) maintained in BMM-
dc (Figure 5D), confirming the key role of TGFbR kinase-depen-
dent signaling in regulating the DSB repair machinery.
TGFbR-SMAD3 Regulates the Sensitivity of Leukemia
Cells to PARPi ± TKi in the BMM
TGFbR kinase activates numerous downstream signaling effec-
tors, including the transcriptionally active SMAD2/3/4 complex
and several kinases (e.g., PI3K, RAF1, PAK1, TAK1) (Vander
Ark et al., 2018). In addition, miR-182 and miR-183 were impli-
cated in TGF-b1-mediated signaling in cancer (Liu et al., 2018;
Zhou et al., 2019).
To identify the downstream mechanisms responsible for
TGFbR-mediated resistance to PARPi, murine AML-like
FLT3(ITD);Tet2/ cells were treated in BMM-dc conditions
with olaparib ± quizartinib in the presence of SMAD3, PI3K,
RAF1, PAK1, and TAK1 inhibitors. Remarkably, only the
SMAD3 inhibitor (SMAD3i) sensitized leukemia cells to olaparib
± quizartinib (Figure 6A), whichwas associated with the inhibition
of the expression of all five DSB repair genes downregulated also
by TGFbRi: ATM, BRCA1, BRCA2, PRKDC, and LIG4 at the
mRNA (Figure 6B) and protein (Figure 6C) levels. The PI3K,
RAF1, PAK1, and TAK1 inhibitors exerted inhibitory effects
only against BRCA1 and/or BRCA2 expression (Figure S6A).
The key role of SMAD3 downstream of TGFbR in triggering
PARPi resistance in BMM-dc was validated by showing that
the inhibition of the activated phospho-SMAD3 by
SMAD3(D407E) dominant-negative mutant restored the sensi-
tivity of FLT3(ITD);Tet2/ AML-like cells to olaparib ± quizartinib
(Figure 6D), whichwas associatedwith the downregulation of the
ATM, BRCA1, BRCA2, DNA-PKcs, and LIG4 proteins (Figure 6E).
Interestingly, putative SMAD2/3/4 binding sites were found in the
promoter regions of all five genes encoding these DSB repair
proteins (Figure 6F). Quantitative chromatin immunoprecipita-
tion (ChIP) analysis indicated that SMAD3 binds to these pro-
moters (Figure 6G), and luciferase-based transactivation assays
confirmed that SMAD3 can induce the transactivation of these
genes (Figures 6H and 6I). The partial inhibition of the transacti-
vation of some genes (e.g., ATM, DNA-PKcs, and LIG4 by
SMAD3i SIS3) (Figure 6I), when compared to the strong downre-
gulation of these genes at the mRNA and protein levels (Figures
6B and 6C, respectively) may be due to experimental limitations
and/or indicate SMAD3-dependent post-transcriptional
modifications.
Since in the BMM-dc the expression of neither miR-182 nor
miR-183 is affected by the CRISPR-Cas9-mediated downregu-
lation of TGFbR2 in the CML-BP K562 cell line and by the
SB431542-mediated inhibition of TGFbR kinase signaling in
AML primary cells (Figure S6B), we postulate that miR-182 and
miR-183 do not play a significant role in the regulation of
TGFbR-mediated sensitivity to olaparib in leukemia cells.
DISCUSSION
Preclinical studies and clinical trials indicated that tumor cells ac-
quire PARPi resistance during treatment, which is usually associ-
ated with the restoration of HR, the loss of PARP1 expression,
and/or the loss of DSB end resection regulation (reviewed inD’An-
drea, 2018). Here, we report that HR/D-NHEJ-deficient PARPi-
sensitive hematopoietic malignant cells are refractory to PARPi
in conditions mimicking the BMM. Hypoxia-induced overexpres-
sion of TGFbR1/2 by leukemia cells combinedwith the production
of TGF-b1 by stromal cells resulted in the stimulation of the TGFbR
serine/threonine kinase-SMAD2/3 canonical pathway in malig-
nant cells. Targeting of TGFbR kinase and SMAD3 reduced the
expression of key genes involved in DNA repair (ATM, BRCA1,
BRCA2, DNA-PKcs, LIG4), inhibited HR and D-NHEJ activities
and restored the sensitivity of malignant hematopoietic cells to
PARPi-mediated synthetic lethality. In summary, we identified
an unexpected mechanism of resistance to PARPi, which de-
pends on the TGF-b1-mediated activation of TGFbR kinase intra-
cellular signaling in leukemia cells in BM. It is likely that not only
leukemia cells but also solid tumor cells metastatic to BM may
be protected from PARPi-mediated synthetic lethality.
We reported before that the TKi-mediated inhibition of OTK
activity in PBM induced HR/D-NHEJ deficiency (downregulation
of BRCA1, RAD51 and LIG4) and sensitivity of quiescent and
proliferating LSCs to PARPi (Maifrede et al., 2018; Nieborow-
ska-Skorska et al., 2017a, 2017b; Sullivan-Reed et al., 2018).
Figure 4. TGFbRi Enhanced Anti-Leukemia Effect of PARPi + TKi
(A) Experimental scheme. Leukemia-bearing mice were treated for 7 consecutive days with TGFbRi (10 mg/kg SB431542), TKi (100 mg/kg imatinib or 1 mg/kg
quizartinib) + PARPi (0.165 mg/kg talazoparib), and the combination of TKi + PARPi + TGFbRi.
(B) Results represent mean % of GFP+ cells in peripheral blood leukocytes (PBLs), spleen cells (SPLs), and BM cells (BMC) ± SDs from 4–6 mice/group bearing
BCR-ABL1 CML-like disease and FLT3(ITD);Tet2/AML-like disease following treatment with vehicle (black bars), SB431542 (violet bars), TKi (imatinib for BCR-
ABL1 CML-like and quizartinib for FLT3[ITD];Tet2/ AML-like disease) + talazoparib (blue bars) and TKi + talazoparib + SB431542 (orange bars). *p < 0.05 when
compared to TKi + PARPi.
(C) Survival curves and median survival time (MST) of mice bearing a primary leukemia and treated as indicated (n = 10 mice per group); *p < 0.001 versus TKi +
PARPi.
(D) Survival curves and MST of secondary transplant mice (n = 6 mice per group); *p < 0.001 versus TKi + PARPi.
(E and F) Representative images (2003 and 4003magnification) of hematoxylin-stained BM tissues from (E) BCR-ABL1 CML-like mice and (F) FLT3(ITD);Tet2/
AML-like mice treated as indicated; GFP+ cells are stained in brown.




Since OTK-positive leukemia cells are resistant to TKi in the
BMM (Krause and Scadden, 2015), our findings that TGFbRi
can mimic the PBM-specific effect of TKi to induce HR/D-
NHEJ deficiency in the BMM (downregulation of BRCA1,
BRCA2, DNA-PKcs, and LIG4)may have a direct impact on plan-
ning therapeutic approaches. Multiple TGFbR kinase inhibitors
(galunisertib = LY2157299, TEW-7197, vactosertib,
LY3200882) and a TGF-b inhibitor (AVID200) have already
entered clinical trials in diverse malignancies; our findings
demonstrating the rationale to target TGFbR may lead to pro-
spective therapeutic applications aimed at eliminating HR/D-
NHEJ-deficient tumor cells from the BM niche.
Figure 5. TGFbR Kinase Regulated Accumulation and Repair of DSBs in Leukemia Cells in the BMM
(A) Left panel: murine FLT3(ITD);Tet2/ AML-like cells (3 mice) were treated with diluent (-), 10 mMolaparib (O), 200 nM quizartininb (Q), and the combination (O +
Q) in BMM-dc (OP9 stromal cells) in the absence and presence of 10 mM SB431542 (black and orange bars, respectively). The results represent % of tail DNA ±
SD in the neutral comet assay. *p < 0.05 when compared to the results in BMM-dc. Right panel: representative images of the comets in the indicated conditions.
(B) Western blots showing expression of g-H2AX and H2AX in nuclear lysates from FLT3(ITD);Tet2/AML-like cells treated as indicated in (A).
(C) Left panel: HR, D-NHEJ, and Alt-NHEJ repair activities were examined in murine FLT3(ITD);Tet2/ AML-like cells in BMM-dc in the presence (orange bars)
and absence (black bars) of 10 mMSB431542. *p < 0.05 when compared to the results in untreated cells. Right panel: scheme of the DSB repair reporter assays.
All of the reporter cassettes contain unique I-SceI endonuclease restriction sites to induce DSBs triggered by the ectopic expression of I-SceI. The DR-GFP
reporter was used to examine HR. GF▌P is a modified GFP gene containing I-SceI site and in-frame stop codons. An internal GFP fragment (iGFP) serves as a
template for HR repair, resulting in a functionalGFP gene. The EJ5-GFP reporter was used to examine D-NHEJ.GFP is separated from a promoter by a puromycin
gene flanked by 2 I-SceI sites. The excision of the puromycin gene and D-NHEJ joins the promoter with GFP, thus creating a functional GFP gene. The EJ2-GFP
reporter was used to examine Alt-NHEJ.GFP is separated from an N-terminal tag (NLS/Zinc-finger) by the I-SceI site and stop codon, which are flanked by 8 nt of
microhomology. Alt-NHEJ repair results in a functional GFP gene by restoring the coding frame between the tag and GFP.
(D) Western blots showing the expression of indicated proteins in nuclear lysates from FLT3(ITD);Tet2/ AML-like cells treated or not with 10 mMSB431542, and
in K562-wt and TGFbR2-depleted K562-Cr cells in BMM-dc (stromal cells indicated at the bottom).
See also Figure S5.




CXCL12-CXCR4 signaling has been often implicated in che-
moresistance and TKi resistance of leukemia cells in the BMM
(Arrigoni et al., 2018; Karantanou et al., 2018; Zeng et al.,
2009). We show that while CXCL12-CXCR4 inhibitors do
enhance the sensitivity to TKi in the BMM, they do not affect
the sensitivity to PARPi. In striking contrast, the inhibition of
the TGFbR kinase-SMAD3 pathway in the BMM sensitized leu-
kemia cells to both TKi and PARPi. Notably, the simultaneous in-
hibition of CXCR4 and TGFbR did not further enhance the
response to PARPi and TKi. Therefore, while our data support
the observation that the TGFbR-SMAD3-CXCR4 axis may regu-
late the sensitivity of leukemia cells to TKi (Nakamura et al.,
2015), PARPi resistance appears to be triggered by a different
TGFbR-SMAD3-dependent mechanism.
Figure 6. SMAD3 Regulates the Expression of DSB Repair Proteins in the BMM
(A) Murine FLT3(ITD);Tet2/ Lin-cKit+ AML-like cells in BMM-dc were left untreated or treated with 1.5 mM olaparib ± 40 nM quizartinib, and 3 mM SMAD3
inhibitor SIS3, 5 mMPI3Ki buparlisib, 2 mMRAF1i LY3009120, 5 mM PAK1i IPA-3, 10 mM TAK1i Takinib, or vehicle for 72 h, followed by plating in methylcellulose.
The results represent mean % colonies ± SDs when compared to untreated cells; *p < 0.05 compared to vehicle.
(B) Real-time RT-PCR detecting mRNA levels of the indicated genes in FLT3(ITD) MV-4-11 cells treated with 10 mMSMAD3 inhibitor SIS3 for 24, 48, and 72 h. The
results represent the mean ± SD fold change of the mRNA level (2-DDCt) when compared to the vehicle-treated control and normalized to 18SrRNA levels.
(C) Western analysis of the indicated proteins in nuclear lysates from murine FLT3(ITD);Tet2/ cells treated for 72 h with 3 mM SMAD3i SIS3 or vehicle (control).
(D) Clonogenic activity of murine FLT3(ITD);Tet2/ GFP+ cells expressing SMAD3(WT) (black bars) or SMAD3(D407E) (orange bars) and treated with 1.5 mM
olaparib (O), 40 nM quizartinib (Q), and O + Q. The results represent mean% colonies ± SDs when compared to untreated cells; *p < 0.05 compared to wild type.
(E) Western blot analysis of the indicated DSB repair proteins and pSMAD3, SMAD3, and FLAG-SMAD3(WT) and FLAG-SMAD3(D407E) in nuclear lysates from
murine FLT3(ITD);Tet2/ GFP+ cells expressing SMAD3(WT) or SMAD3(D407E).
(F) Putative SMAD2/3/4-binding sites in the promoter regions of ATM, BRCA1, BRCA2, PRKDC (encodes DNA-PKcs), and LIG4 detected in the genomic se-
quences using matrix scan and Markov chain background models. The arrows mark the start of the transcription binding sites. Yellow areas and red and blue
boxes: fragments detected or tested in (G), (H) and (I), respectively.
(G) ChIP followed by real-time PCR to detect SMAD3 binding toATM,BRCA1,BRCA2,PRKDC, and LIG4 promoter regions in AML cells cultured in BMM-dc. The
data show mean % DNA input ± SDs; *p < 0.05.
(H) Transactivation activity of the luciferase reporters carrying ATM, BRCA1, BRCA2, PRKDC, and LIG4 promoter regions in 293T cells transfected with
SMAD3(WT), SMAD3(D407W), or empty plasmid. The data show the relative change of the promoter region-driven transactivation versus control transfected with
empty plasmid ± SD; *p < 0.05.
(I) Transactivation activity of the luciferase reporters carrying ATM, BRCA1, BRCA2, PRKDC and LIG4 promoter regions in MV4-11 cells treated with SIS3 or
vehicle (control). The data show% of the promoter-driven Gaussia luciferase (GL)/constitutively expressed secreted alkaline phosphatase (SEAP) activity ± SD;
*p < 0.05.
See also Figure S6.




Remarkably, we discovered that the resistance of leukemia
cells to PARPi-mediated synthetic lethality in BMM-like condi-
tions depended on the TGFbR kinase-SMAD3 fostered expres-
sion of the genes playing a key role in DNA damage recognition
(ATM) and in DSB repair by HR (BRCA1, BRCA2) and D-NHEJ
(DNA-PKcs, LIG4). ATM-mediated g-H2AX at DSB sites is
required for the initiation of DSB repair (Bonner et al., 2008).
HR and D-NHEJ repair DSBs in proliferating cells, D-NHEJ plays
amajor role in quiescent cells, and Alt-NHEJ serves as backup in
both proliferating and quiescent cells (Feng et al., 2011; Karanam
et al., 2012). We observed that the inhibition of TGFbR kinase not
only reduced the ability to sense DSBs (downregulation of ATM-
mediated g-H2AX) but also altered the capability of DSB repair
(downregulation of both HR and D-NHEJ activities and most
likely compensatory elevation of Alt-NHEJ). As a result, both
proliferating and quiescent leukemia cells became highly sensi-
tive to PARPi in BMM-like conditions. This conclusion is sup-
ported by our previous report that PARPi was very effective
against HR and D-NHEJ-deficient proliferating and D-NHEJ-
deficient quiescent leukemia stem cells in PBM-like conditions
(Nieborowska-Skorska et al., 2017b).
There are conflicting reports about the impact of TGF-b1-
TGFbR signaling on DSB repair indicating positive and negative
effects on the expression of the genes and/or activities of the HR
and/or D-NHEJ/Alt-NHEJ pathways (reviewed in Liu et al., 2019).
These discrepancies most likely depend on distinct epigenomes
(distinct gene expression programs), tumor tissue type (hemato-
logic malignancies, carcinomas, or non-transformed cells), and
tumor microenvironment conditions (normoxia versus hypoxia,
presence or absence of stromal cells) (Chan et al., 2010; Tu-
fegdzic Vidakovic et al., 2015). We combined hypoxia with the
presence of stromal cells in 2- and 3-dimensional co-culture to
better mimic in vitro BMM-like conditions. Moreover, the critical
role of TGFbR kinase signaling in the BMM-dependent
resistance of hematologic malignancies to the PARPi ± TKi com-
bination identified by us in vitro was validated in vivo by demon-
strating that the pharmacological inhibitor of TGFbR kinase
enhanced the anti-leukemia effect of PARPi + TKi in the BM
but not in the PB of SCID mice.
It is worth considering that genetic aberrations may dictate the
role of TGF-b1-TGFbR kinase-dependent signaling in the DNA
damage response. We postulate that TGFbRi reduces HR and
D-NHEJ activity and sensitizes hematopoietic malignancies
driven by OTKs such as FLT3(ITD), JAK2(V617F), and BCR-
ABL1 to PARPi ± TKi in the BMM. Of note, the mutation-depen-
dent disruption of FANCD2, FANCA, and FANCG (Fanconi
anemia [FA] pathway) caused transcriptional changes that re-
sulted in hyperactive TGF-b signaling in hematopoietic stem
cells, and the inhibition of the TGF-b pathway in FA cells dimin-
ished NHEJ but promoted HR activity (Zhang et al., 2016). There-
fore, the anti-leukemia effect of TGFbRi combined with PARPi
may be limited in the BM of FA patients.
In conclusion, we discovered an intrinsic mechanism of
resistance to PARPi, which depends on the TGF-b1-mediated
activation of TGFbR kinase-SMAD2/3 signaling, resulting in the
stimulation of DSB repair by HR and D-NHEJ in hematopoietic
malignant cells residing in the BM. Although we excluded the
CXCL12-CXCR4 axis, additional mechanisms may complement
TGF-b1-TGFbR kinase-SMAD2/3 signaling to induce PARPi
resistance in BMM.
We postulate that the pharmacological targeting of the TGFbR
kinase can improve therapeutic outcomes in leukemic patients
receiving PARPis and other drugs, whose activities are limited
in the BM niche due to enhanced DSB repair (Zhou et al.,
2016). A similar approach may also be applied to treat solid tu-
mors (Liu et al., 2018). In addition, tumors carrying TGFBR2 de-
letions/mutations should be responsive to PARPi in the BMM
(The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Con-
sortium, 2020).
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DNA Polymerase q Invitrogen Cat# PA5-69577; RRID:AB_2688722
Lamin Abcam Cat# ab-16048; RRID:AB_10107828
b-actin Santa Cruz Biotechnology Cat# sc-47778; RRID:AB_2714189
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REAGENT or RESOURCE SOURCE IDENTIFIER
Biological Samples
Murine femoral bone marrow tissue
specimens
This paper N/A
Murine tail vein peripheral blood This paper N/A
Murine spleen specimens This paper N/A
Chemicals, Peptides, and Recombinant Proteins
SB435142 (TGFbR inhibitor) Selleckchem Cat# S1067
Galunisertib (TGFbR inhibitor) Selleckchem Cat# S2230
AMD3100 (CXCR4i antagonist) Selleckchem Cat# S8030
WZ811(CXCR4i antagonist) Selleckchem Cat# S2912
Olaparib (PARP inhibitor) Selleckchem Cat# S1060
Talazoparib (PARP inhibitor) Selleckchem Cat# S7048
Quizartinib (FLT3 inhibitor) Selleckchem Cat# S1526
Imatinib (ABL inhibitor) Selleckchem Cat# S2475
SIS3 (SMAD3 inhibitor) Selleckchem Cat# S7959
Buparlisib (PI3K inhibitor) Selleckchem Cat# S2247
LY3009120 (RAF inhibitor) Selleckchem Cat# S7842
IPA-3 (PAK1 inhibitor) Selleckchem Cat# S7093
Takinib (TAK1 inhibitor) Selleckchem Cat# S8663
4-hydroxytamoxifen Sigma Aldrich Cat# H7904
TGF-b1 (human) Invitrogen Cat# PHG9204
TGF-b1 (mouse) R&D Systems Cat# 7666-MB-005
SCF (human) StemCell Technologies Cat# 78155.2
SCF (mouse) StemCell Technologies Cat# 78064.2
FLT3 Stem Cell Technologies Cat# 78137.2
IL-3 (human) StemCell Technologies Cat# 78040.2
IL-3 (mouse) PeproTech Cat# 213-13
IL-6 StemCell Technologies Cat# 78050.2
G-CSF StemCell Technologies Cat# 78012.2
TPO PeproTech Cat# 300-18
Cell Proliferation Dye eFluor 670 Invitrogen Cat# 65-0840
RIPA buffer Thermo Fisher Scientific Cat# 89900
Pierce ECL Western Blotting Substrate Thermo Fisher Scientific Cat# 32106
I-SceI Thermo Fisher Scientific Cat# ER1771
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Q5 High-Fidelity DNA polymerase New England Biolabs Cat# M0491
Lipofectamine 2000 Invitrogen Cat# 11668019
Cell line Nucleofector kit V Lonza Cat# VCA-1003
Polybrene Sigma Cat# TR-1003
Critical Commercial Assays
OxiSelect Comet Assay Kit Cell Biolabs Cat# STA-351
EasySep mouse hematopoietic progenitor
cell isolation kit
StemCell Technologies Cat# 19856
EasySep mouse CD117 (KIT) positive
selection kit
StemCell Technologies Cat# 18757
EasySep human hematopoietic progenitor
cell enrichment kit
StemCell Technologies Cat# 14056
EasySep human hematopoietic CD34
positive selection kit
StemCell Technologies Cat# 17856
4-20% Mini-PROTEAN TGX Precast
Protein Gels
BioRad Cat# 4561094
Nitrocellulose membrane Thermo Fisher Scientific Cat# 88018
Human/Mouse TGF-b1 ELISA Ready-SET-
Go! Kit
eBioscience Cat# 88-8350
miRNeasy Micro Kit QIAGEN Cat# 217084
Cell Line Nucleofector kit V Lonza Cat# VCA-1003
Secrete-Pair Dual Luminescence Assay Kit GeneCopoeia Cat# LF031
Dual-Glo Luciferase assay System Promega Cat# E2920
Total RNA Mini columns A&A Biotechnology Cat# 031-100
0.45-mM PES filter Millipore Cat# SLHP033RS
PerFix EXPOSE kit Beckman Coulter Cat# B26976
Experimental Models: Cell Lines
HS-5 ATCC Cat# CRL-11882; RRID:CVCL_3720
HS-5-TGFb1 CRISPR/Cas9 knock-down This paper N/A
OP-9 ATCC Cat# CRL-2749; RRID:CVCL_4398
K562 ATCC Cat# CCL-243; RRID:CVCL_0004
K562-TGFbR2 CRISPR/Cas9 knock-down Applied Biological Materials Inc. Cat# NM_003242
Kasumi-1 ATCC Cat# CRL-2724; RRID:CVCL_0589
MV4-11 ATCC Cat# CRL-9591; RRID:CVCL_0064
HEK293T/17 ATCC Cat# CRL-11268; RRID:CVCL_1926
Experimental Models: Organisms/Strains
NOD.Cg-Prkdcscid/J mice Jackson Laboratory Cat# 001303; RRID:IMSR_JAX:001303
B6.Cg-Ndor1Tg(UBC-cre/ERT2)1Ejb/1J mice Jackson Laboratory Cat# 007001; RRID:IMSR_JAX:007001
B6N.129S6(SJL)-Jak2tm1.2Ble/AmlyJ mice Jackson Laboratory Cat# 031658; RRID:IMSR_JAX:031658
B6;129-Tgfbr2tm1Karl/J Jackson Laboratory Cat# 012603; RRID:IMSR_JAX:012603
Vav-cre mice Jackson Laboratory Cat# 018968; RRID:IMSR_JAX:018968
Human AML cells https://www.nejm.org/doi/full/
10.1056/NEJMoa1112304
N/A
Human CML and AML cells https://www.jci.org/articles/view/90825 N/A




Human normal bone marrow (CD34+) cells StemCell Technologies https://www.stemcell.com/human-
bone-marrow-cd34-cells-frozen.html
(Continued on next page)





REAGENT or RESOURCE SOURCE IDENTIFIER
Human primary bonemarrowmesenchymal
stromal cells
StemCell Technologies Cat #70022
Oligonucleotides
Forward primer for JAK2(V617F) genotype:
CGT GCA TAG TGT CTG TGG AAG TC
This paper N/A
Reverse primer for JAK2(V617F) genotype:
CGT GGA GAG TCT GTA AGG CTC AA
This paper N/A
Forward primer for UBC-Cre: GCA TTA
CCG GTC GAT GCA ACG AGT GAT GAG
This paper N/A
Reverse primer for UBC-Cre: GAG TGA
ACG AAC CTG GTC GAA ATC AGT GCG
This paper N/A
Forward primer for TGFbR2fl/fl genotype:
TAA ACA AGG TCC GGA GCC CA
This paper N/A
Reverse primer for TGFbR2fl/fl genotype:
ACT TCT GCA AGA GGT CCC CT
This paper N/A
Primers for ChIP – real-time PCR:
See Table S2
This paper N/A
Primers for real-time RT-PCR: See Table S1 This paper N/A
Primers for generation of transactivation


































pLenti7.3-redluc Invitrogen Cat #V53406
pCL-ECO https://jvi.asm.org/content/70/8/5701.long Addgene Cat# 12371
BRCA1: pEZX-PG04.1 GeneCopoeia Cat# HPRM47192-PG04
BRCA2: pEZX-PG04.1 GeneCopoeia Cat# HPRM30044-PG04
ATM: pEZX-PG04.1 GeneCopoeia Cat# HPRM30037-PG04
Lig4: pEZX-PG04.1 GeneCopoeia Cat# HPRM44240-PG04
PRKDC: pEZX-PG04.1 GeneCopoeia Cat# HPRM33722-PG04
pGL3-Basic Promega Cat# E1751
pGL4.73 Promega Cat# E6911
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Any further inquiries, questions, requests about methodological resources, reagents or experimental procedures can be directly ad-
dressed to and will be clarified by the Lead Contact, Tomasz Skorski (tskorski@temple.edu).
Materials Availability
This study did not produce new reagents, chemicals or plasmids.
Data and Code Availability
This study did not generate any datasets or codes.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
In vitro studies
Human malignant and normal hematopoietic cells
FLT3(ITD);TET2mut, FLT3(ITD);AML1-ETO and AML1-ETO –positive primary AML samples were from the ECOG-ACRIN E1900
clinical trial (Patel et al., 2012). JAK2(V617F);TET2mut and BRCA1/2-deficient AML samples were described before (Nieborow-
ska-Skorska et al., 2017a, 2017b). BCR-ABL1 –positive CML-CP samples were obtained from the Medical University of Vienna
and Ludwig-Boltzmann Institute for Hematology and Oncology, Vienna, Austria. Samples of normal hematopoietic cells were pur-
chased from StemCell Technologies (Vancouver, Canada). Lin-CD34+ cells were obtained from mononuclear fractions by magnetic
sorting using the EasySep Lin negative selection cocktail followed by CD34 positive selection (StemCell Technologies) as described
before (Nieborowska-Skorska et al., 2017b). CML-BP K562 cells, AML MV4-11 cells and Kasumi-1 cells were from ATCC. TGFbR2
CRISPR/Cas9 knock-down K562-Cr cells were from Applied Biological Materials Inc. (Vancouver, Canada). These leukemic cell lines
were maintained in DMEM supplemented with 10% FBS, L-glutamine and antibiotics in 37C.
Continued
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Software and Algorithms
ImageJ OpenComet https://imagej.nih.gov/ij/
SigmaPlot Systat software https://systatsoftware.com/products/
sigmaplot/
FlowJo BD Biosciences https://www.flowjo.com/solutions/flowjo
Excel Microsoft https://www.microsoft.com/
en-us/microsoft-365/excel
































accessed using one of the WSDL client
programs, available for download on the
wiki page of the Nencki Genomics
Database http://www.nencki-genomics.
org/wiki/doku.php?id=tutorial:webservices




Murine malignant hematopoietic cells
Tet2fl/fl (Moran-Crusio et al., 2011) and Parp1/ (Nieborowska-Skorska et al., 2017b) mice were crossed to FLT3(ITD) (Lee et al.,
2007) and Vav-CRE (Georgiades et al., 2002) strains to generate FLT3(ITD);Tet2/ and FLT3(ITD);Tet2/;Parp1/ mice.
UBC-CreERT2 (B6.Cg-Ndor1Tg(UBC-cre/ERT2)1Ejb/1J), JAK2V617F/+ (B6N.129S6(SJL)-Jak2tm1.2Ble/AmlyJ) and Tgfbr2f/f (B6;129-
Tgfbr2tm1Karl/J) mice (Jackson Laboratories) were crossed to generate UBC-CreERT2;JAK2V617F/+;Tgfbr2f/f and UBC-CreERT2;
JAK2V617F/+;Tgfbr2+/+mice. The primers used for mice genotyping are listed in Table S1. The Institutional Animal Care and Use Com-
mittee atWashington University approved all animal procedures. JAK2(V617F);Tgfbr2/ and JAK2(V617F);Tgfbr2+/+ bonemarrow
cells were obtained after activation of Cre recombinase during 7 days incubation with 1 mM 4-hydroxytamoxifen (Sigma Aldrich).
Expression of JAK2(V617F) and depletion of Tgfbr2 was confirmed by immunofluorescence. Lin-cKit+ cells were obtained from
mononuclear fractions by magnetic sorting using the EasySep Lin negative selection followed by cKit positive selection cocktail
(StemCell Technologies) as described before (Nieborowska-Skorska et al., 2017b).
Bone marrow (BM) stromal cells
Monolayers of human BMmesenchymal stromal cells (StemCell Technologies) weremaintained inMesenCultTM Proliferation kit sup-
plemented with mesenchymal stem cell stimulatory supplements (StemCell Technologies). Primary autologous stroma cells mono-
layers were established as described by Schelker et al. (Schelker et al., 2018) with modifications. Briefly, a leukemic mouse BM cells
and AML patient’s BM cells were cultivated for 7-10 days in 48-well plate in DMEM supplemented with 10% FBS, L-glutamine and
antibiotics to establish stroma cells monolayer. HS-5 and OP9 cells (ATCC) were cultured in DMEM supplemented with 10% FBS, L-
glutamine and antibiotics.
Animal studies
Twelve weeks-old NOD.Cg-Prkdcscid/J (SCID) female mice were purchased from The Jackson Laboratory. SCIDmice bearing GFP+
BCR-ABL1 CML-like or GFP+ FLT3(ITD);Tet2/ AML-like murine leukemias (10%–20%GFP+ leukemia cells in total tail vein blood
leukocytes) were treated for 7 consecutive days with vehicle, TKi (100 mg/kg imatinib or 1 mg/kg quizartinib) + PARPi (0.165 mg/kg
talazoparib) as described before (Maifrede et al., 2018; Nieborowska-Skorska et al., 2017b), TGFbRi (10mg/kg SB431542) (Shi et al.,
2017) and the combination of TKi + PARPi + TGFbRi (Selleckchem). GFP+ leukemia cells were detected by flow cytometry in periph-
eral blood leukocytes (PBL), splenocytes (SPL) and bone marrow cells (BMC) 3 days after the end of treatment. Moreover, 1 3 106
femoral bonemarrow cells were transplanted into the sub-lethally irradiated secondary recipients to assess the effect of treatment on
LSCs. Median survival time (MST) of the primary and secondary recipients was determined by Kaplan-Meier survival analysis. The
Institutional Animal Care and Use Committee at Temple University approved all animal procedures and the experimental mice were
maintained under a completely pathology-free condition and standard feeding diet in the animal facility of Temple University.
METHOD DETAILS
BMM and PBM experiments
Tomimic BMM, normal andmalignant hematopoietic cells were co-cultured in direct contact (BMM-dc) with stromal cell monolayers
(1:1 ratio) in serum-free medium StemSpanTM SFEM II (StemCell Technologies) supplemented with recombinant growth factors,
including 100 ng/mL SCF, 100 ng/mL FLT3, 20 ng/mL IL-3, 20 ng/mL IL-6, 20 ng/mLG-CSF and 100 ng/mL TPO as described before
(Maifrede et al., 2018; Nieborowska-Skorska et al., 2017a; Nieborowska-Skorska et al., 2017b) in hypoxia (1% O2) in 37
C. BMM
indirect contact (BMM-idc) condition was achieved by separation of stroma and hematopoietic cells with a 0.4 mm PET cell culture
insert (Millipore). BMM-cm was achieved by maintaining leukemia cells in 24 hours-conditioned medium from HS-5 cells in hypoxia.
PBM condition was mimicked by maintaining malignant and normal hematopoietic cells in liquid culture in normoxia (17% O2) in the
absence of stroma. After 24 hours, inhibitors (listed in the Key Resources Table) were added for 3-5 days followed by evaluation of
normal and malignant cells clonogenic activity in MethoCult H4230 (StemCell Technologies), number of Lin-CD34+CD38-CFSEmax
quiescent cells [flow cytometry using Cell Proliferation Dye eFluor 670 (Invitrogen), Linage cocktail, CD34 and CD38 antibodies
(BD Biosciences)], and cell cycle (propidium iodide staining) as described before (Maifrede et al., 2018; Nieborowska-Skorska
et al., 2017a; Nieborowska-Skorska et al., 2017b; Podszywalow-Bartnicka et al., 2019).
BMM three-dimensional (BMM-3d) co-culture
MV4-11 cells were lentivirally transfected with plasmid pLenti7.3-redluc expressing GFP and Firefly luciferase (Invitrogen), followed
by sorting of GFP+ cells. Co-culture in spheres was achieved by seeding 1000 of MV4-11 cells with 2000 of HS-5 cells in 5%
MatrigelTM (Corning) in IMDM medium supplemented with L-glutamine, in a non-adhesive 96 well U-bottom plates (BD Falcon).
Seven days later cells were treated for 72h in hypoxia as indicated. Luciferase was assayed using luciferase kit (Promega) and
luminescence was measured using Promega Glomax 20/20 luminometer. Protein level in the cell lysates was measured using
Bradford solution.
Western blot
Nuclear and total cell lysates were obtained by nuclear lysis buffer and RIPA buffer (Thermo Fisher Scientific) as described before
(Cramer-Morales et al., 2013) and analyzed by immunoblotting with primary antibodies listed in the Key Resources Table. In the




procedure, proteins in cell lysates were separated by SDS-PAGE in gradient (4%–20%) Mini-PROTEAN TGX Precast Protein Gels
(BioRad). The gels were then transferred into nitrocellulose membranes (Thermo Fisher Scientific) at 4C by 105 voltage in one
hour. To conduct immunoblotting analysis, the membranes were blocked with 5% fat-free milk/BSA solution in one hour at
room temperature and primary antibodies were added at desired concentration and incubated overnight at 4C with gentle
shaking. The following day, the membranes were washed thoroughly and given in solution of HRP-conjugated rabbit/mouse
anti-IgG antibodies (Millipore) in one hour at room temperature. Protein blots were detected in Premium X-Ray Film (Phenix) by
Pierce ECL Western Blotting Substrate (Thermo Fisher Scientific). Lamin and b-actin were used as the loading controls for nuclear
and total cell lysates, respectively.
Downregulation of TGF-b1 in HS-5 cells
TGF-b1 in HS-5 cells was downregulated by CRISPR/Cas9. Briefly, guide RNAs (gRNAs) targeting TGF-b1 were generated using
CRISPR Design and cloned into the lentiCRISPRv2 vector. The lentiCRISPRv2 vector (Stringer et al., 2019) with a gRNA insert,
the packaging plasmid psPAX2, and the envelope plasmid VSVG were mixed together and packed in HEK293T cells using Fugene
6. Lentiviruses were harvested at 48 and 72 h respectively. Then, HS-5 cells were infected at 50% confluency with freshly collected
CRISPR-Cas9-gRNA lentivirus supplemented with 8 mg/ml polybrene for 48h. Infected cells were selected in media with puromycin
(1 mg/ml) for up to 14 days. Successful mutation of infected HS-5 cell lines was confirmed with T7E1 assay. Secretion of TGF-b1 was
tested in supernatants of cell lines cultured in serum free conditions (to avoid background detection of bovine serum TGF-b) by ELISA
method using Human/Mouse TGF-b1 ELISA Ready-SET-Go! Kit (eBioscience). Prior to ELISA, cell culture supernatants were first
acidified to enable detection also of latent TGF-b1. In brief, 96-well Nunc MaxiSorp plates (Invitrogen, Carlsbad) were first coated
with capture antibody overnight and then supernatants were incubated in wells for 2h at RT. Afterward, biotinylated detection anti-
body and streptavidin-HRP were added to detect the amount of TGF-b1 by enzymatic colorimetric reaction. Absorbance was
measured at 450nm using Tecan Sunrise spectrophotometer and X-fluor software. Final concentrations of TGF-b1 in cell culture su-
pernatants were calculated based on the standard curve equation.
Retroviral infections
Dominant-negative murine SMAD3(D407E) mutant and SMAD3 wild-type (WT) cDNAs were obtained from Dr. Mitsuyasu Kato (Goto
et al., 1998) and were re-cloned to pMIG-IRES-GFP retroviral construct. Retroviruses were prepared by co-transfecting HEK293T/17
cells (ATCC CRL-11268) in a 10-cm plate with 10 mg of packaging pCL-ECO plasmid (Addgene #12371) and 10 mg MIGR1 based
vectors by using Lipofectamine 2000 transfection reagent (Invirtogen) according to manufacturer’s protocol. Viruses were harvested
40h and 64h after the transfection and filtered through a 0.45-mmPES filter (Millipore). For infection, 53 105 cells were suspended in
1 mL of virus-containing medium containing 6 mg/ml polybrene (Sigma) and supplemented with recombinant growth factors,
including 100 ng/mL SCF, 100 ng/mL FLT3, 20 ng/mL IL-3, and 20 ng/mL IL-6. GFP+ cells were obtained by fluorescent cell sorting
48 hr after the initial infection as described before (Dasgupta et al., 2016).
DNA damage/repair
Neutral comet assay was performed by cell-agarose electrophoresis in Tris-Acetic acid-EDTA buffer based on OxiSelect Comet
Assay Kit (Cell Biolabs) and comet DNA tail was considered level of DSB and analyzed by ImageJ software (OpenComet) (Sulli-
van-Reed et al., 2018). HR, D-NHEJ and Alt-NHEJ activities were measured by using DR-GFP (HR), EJ5-GFP (D-NHEJ) and EJ2-
GFP (Alt-NHEJ) reporters (Bennardo et al., 2008; Pierce et al., 1999) as well as endonuclease I-SceI (Thermo Fisher Scientific) to
generate double strand breaks in GFP cassette as described before (Nieborowska-Skorska et al., 2017b). Specific DSB repair ac-
tivity was measured by detection of GFP+ cells.
Immunofluorescence
Cells were washed twice with 1X PBS before getting blocked by 1% bovine serum albumin (BSA) in 1X PBS together with human FC
receptor block solution (Biolegend) in 10 minutes at RT. Primary anti-TGFbR1 (Santa Cruz Biotechnology) and anti-TGFbR2 (Invitro-
gen) antibodies were used and incubated at 4C for 1 hour and followed by adding FITC-conjugated anti-mouse (for TGFbR1) and
anti-rabbit (for TGFbR2) IgG antibodies (Invitrogen) also incubated at 4C for 1 hour. To detect JAK2(V617F) kinase activity cells were
fixed and permeabilized using a PerFix EXPOSE kit according to the manufacturer protocol (Beckman Coulter) followed by staining
with anti-phosphotyrosine 4G10mousemonoclonal antibody conjugated to FITC (Millipore). Cells were washed and re-suspended in
1X PBS before analyzing by flow cytometer and the output was visualized by FlowJo software (BD Biosciences, CA, USA).
Real-time RT-PCR
After incubatingMV4-11 leukemia cells in BMM-dc condition with 10 mMSIS3 (Selleckchem) for 48 and 72 hours, RNA from cell lysate
was isolated by TRI Reagent (Sigma Aldrich) and the Total RNA Mini columns (A&A Biotechnology). Then, 0.5 mg of total RNA was
subjected to reverse transcription (RT) by M-MLV enzyme (Promega) with oligo dT (Bioline), random hexamers (Bioline) and RNase
inhibitor (Blirt) in Promega buffer M-MLV diluted 5x in DEPC-treated water. The real-time RT-PCR master mix contained cDNA tem-
plate (pre-diluted 2x in water), forward and reverse primers 0.5 mM each (listed in Table S2) and SensiFAST SYBR Green Hi-ROX re-
agent (Bioline) and the reaction was conducted in StepOnePlusTM Real-Time PCR System Thermocycler (Thermo Fisher Scientific).




The entire procedures followed the MIQE guidelines. To analyze real-time RT-PCR output, the difference in quantitative mRNA
expression level was estimated by comparative DDCt method and calculated as fold change (2-DDCt) with the expression level of
18SrRNAused for normalization.
ChIP
Cells were fixed in 1% formaldehyde for 15 minutes, and DNA was sonicated using a sonic dismembrator (Thermo Fisher Scientific)
to generate 200–500-bp fragments. Chromatin was immunoprecipitated with anti-SMAD3 antibody (Cell Signaling Technology).
ChIP-grade protein A/G magnetic beads (Pierce) were used for immunoprecipitation with antibody. Real- time PCR was performed
with a master mix containing 1X Maxima SYBR Green, 0.25 mM primers and 1/50 of the ChIP DNA per well. Quantitative PCR reac-
tions were carried out in triplicate using the ABI StepOnePlus PCR system. Data was normalized to DNA input. The primers are listed
in Table S3.
Firefly/Renilla Luciferases transactivation assay
Gene specific promoter fragments containing putative SMAD3 binding sites and transcription start sites flanked by KpnI or XhoI re-
striction sites were generated by PCR using genomic DNA of the normal Lin-CD34+ human bone marrow cells. PCR was performed
by using Q5 High-Fidelity DNA polymerase (New England Biolabs) and primers listed in Table S4. The Firefly luciferase reporter
vectors were created by sub-cloning the gene-specific PCR fragments into the pGL3-basic vector (Promega) by KpnI and XhoI
(Promega) restriction sites. All plasmids were analyzed and confirmed by restriction digestion and DNA sequencing. 293T cells
were co-transfected with pGL4.73 (Renilla normalization vector), pGL3-Basic (Firefly reporter vector) containing gene specific pro-
motor regions, and either with pMIG-empty or pMIG-SMAD3(WT) or pMIG-SMAD3(D407E) vectors using Lipofectamine 2000 (Invi-
trogen). Transfection efficiency was determined by detecting GFP+ cells (50%–60% of the total cell population). Luciferase activity
was measured 60h after transfection. Samples were assayed for Firefly and Renilla luciferase activities using Dual-Glo Luciferase
Assay System (Promega) and normalized according to the manufacturer instructions.
Gaussia Luciferase/Secreted Alkaline Phosphatase transactivation assay
2x106 of MV4-11 cells were transfected with 2 mg of pEZX-PG04.1 plasmids containing the indicated promoter fragments (GeneCo-
poeia) using Cell line Nucleofector kit V (Lonza) and Nucleofector 2b device (Lonza). Then the cells were suspended in the antibiotic-
free growth medium and added to HS-5 cells (plated the preceding day) to start co-culture under hypoxia in the absence or presence
of 10 mM SIS3 (Selleckchem). After 18h the activity of luciferase was detected in the cell culture conditioned medium immediately
after collecting and assayed using Secrete-Pair Dual Luminescence Assay Kit (GeneCopoeia), following manufacturer protocol.
Gaussia Luciferase (GL) activity (which transcription was under control of the studied promotor) was measured in GL-H buffer, as-
suring more sensitive detection. Bioluminescence signal generated by Secreted Alkaline Phosphatase (SEAP) expressed constitu-
tively from the plasmid was measured in parallel for normalization. Luminescence was measured using the Promega Glomax 20/20
luminometer.
Detection of SMAD2/3/4 putative binding sites
These binding sites were detected in the genomic sequences downloaded from Ensembl using command line version of the program
matrix-scan (quick) (Turatsinze et al., 2008) and the pre-computed first order (2-nt.) Markov-chain background models, based on
both strands of the upstream noncoding regions of the genome, e.g., 2nt_upstream-noorf_Homo_sapiens_EnsEMBL-ovlp-2str for
human. The motif scores are converted to p values, based on the distributions of scores computed for each motif using the program
matrix-distrib. A uniform p value threshold of p < 0.0001 is used to call an instance of a particular motif at a given genomic position.
The web service function PlotGenomic plots a graphical representation of selected NGD content in the ± 10 kb flank of the transcrip-
tion start site of a chosen gene, and returns this content as tab-separated files. More precisely, this function returns instances of
selected area types, and instances of selected motif types that intersect any of the returned area instances (Krystkowiak et al.,
2013). We use a comprehensive set of transcription factor binding site (TFBS) motifs from several public motif libraries (Dabrowski
et al., 2015).
MicroRNA quantification
hsa-183-5p, hsa-182-3p, hsa-103a-3p and UniSp6 miRNAs were examined in total cellular RNA enriched in miRNA, isolated from
K562-wt, K562-Cr cells and from Lin-CD34+ FLT3(ITD);TET2mut AML cells treated with 10 mM SB431542 (Selleckchem) or vehicle
using miRNeasy Micro Kit (QIAGEN). The same amounts of RNA were subjected to reverse transcription (performed in triplicates)
followed by real-time PCR. Fold change in miRNA level relative to UniSp6 was calculated as 2-DDCt.
Immunohistochemistry
GFP+ leukemia cells were visualized in formalin-fixed, peroxidases-quenched femoral bone marrow specimens of leukemia-
bearing SCID mice by immunohistochemical staining according to standard methods. The sections of femoral bone marrow tissue
were incubated with primary antibodies to anti-GFP (Invitrogen), immunodetection was performed using the Dako Envision+ poly-
mer system and immunostaining was visualized with the chromogen 3, 30-diaminobenzidine. Hematoxylin-counterstained sections




were viewed with a Nikon Eclipse 50i microscope and photomicrographs were taken with an attached Nikon DS-Fi1 camera (Mel-
ville, NY, USA).
QUANTIFICATION AND STATISTICAL ANALYSIS
All experiments were conducted at least in three independent replications. The mean and standard deviation (SD), and statistical
analysis (p value) was executed by Student’s t test in SigmaPlot (Systat software, CA, USA). Median survival time (MST) of mice
was assessed by Kaplan-Meier log-rank test. Data are considered statistically significant when p value is less than 0.05.
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Figure S2; related to Figure 2. Role of TGF-β1-TGFβR and CXCL12 - CXCR4 signaling in regulating sensitivity of leukemia 
cells to PARPi and TKi in BMM. (A) Human FLT3(ITD);TET2mut Lin-CD34+ AML cells (3 patients) and (B) murine 
FLT3(ITD);Tet2-/- Lin-cKit+ AML-like cells (3 mice) were treated for 72 hrs in BMM-dc conditions with 1 µM olaparib or 100 nM 
quizartinib, and 10 µM TGFβR kinase inhibitor SB431542, 3 ng/ml TGF-β1 neutralizing antibody (1D11), 10 µM CXCR4 inhibitor 
AMD3100, 5 µM CXCR4 antagonist WZ811, or vehicle (-) followed by plating in methylcellulose. Results represent mean % ± SD 





























Figure S3; related to Figure 2. Stromal cells produce TGF-β1. Results represent mean concentration ± SD of TGF-β1 in serum-
free conditioned medium from HS-5, OP9 and bone marrow stroma cells in serum-free medium. 
 
  
Figure S4; related to Figure 3. Inhibition of cell cycle in BMM. Human FLT3(ITD);TET2mut Lin-CD34+ AML cells were 
maintained in PBM or BMM-dc for 48 hrs. (A) Cell cycle analysis performed with propidium iodide. Results represent mean % of 
cells in cell cycle phases ± SD from triplicates; *p<0.05 when compared to PBM. (B) Western blot showing phospho-SMAD2 
(pSMAD2) and SMAD2 in nuclear cell lysates. 
 
 
Figure S5; related to Figure 5. Inhibition of TGFβR kinase does not affect cell cycle progression of FLT3(ITD);TET2mut AML 
cells in BMM. Human FLT3(ITD);TET2mut Lin-CD34+ AML cells (3 patients) were treated for 48 hrs in BMM-dc with 10 µM 
TGFβR kinase inhibitor SB431542 or vehicle. (A) Western blot showing phospho-SMAD2 and SMAD2 in nuclear cell lysates. (B) 
Cell cycle analysis performed with propidium iodide. Results represent mean % ± SD from triplicates. 
 
Figure S6; related to Figure 6. The role of PI3K, RAF, PAK and TAK1 kinases, and miRs 182 and 183 on the 
expression of DSB repair proteins in BMM. (A) Western analysis of the indicated proteins in murine 
FLT3(ITD);Tet2-/- cells treated for 72 hrs with 5 µM PI3Ki buparlisib, 2 µM RAF1i LY3009120, 5 µM PAK1i 
IPA-3, 10 µM TAK1i takinib or vehicle. The effect of specific inhibitors was confirmed by suppression of AKT, 
ERK1/2, and p38MAPK phosphorylation. (B) Expression levels of indicated miRNAs in K562-wt and TGFβR2-
depleted K562-Cr cells, and Lin-CD34+ FLT3(ITD);TET2mut AML primary cells treated with 10 µM SB431542 or 
vehicle. Results show mean Cp value ± SD from 3 independent experiments, each run in 3 independent reverse 
transcription reactions and each reaction in duplicate. miR103a has been analyzed as control, a tumor-suppressor 
miRNA, which is changed in various cancers including myelodysplastic syndrome, however it is not located in the 




Table S1. Primers used for mice genotyping; related to STAR Methods. 
Tet2fl/fl FWD AAG AAT TGC TAC AGG CCT GC 
Tet2fl/fl REV TTC TTT AGC CCT TGC TGA GC 
PARP1 common CAT GTT CGA TGG GAA AGT CCC 
PARP1 wild-type CCA GCG CAG CTC AGA GAA GCC A 
PARP1 mutant CAT GTT CGA TGG GAA AGT CCC 
FLT3(ITD) common TCT GGT TCC ATC CAT CTT CC 
FLT3(ITD) wild-type AGG AAG TCG ATG TTG GCA CT 
FLT3(ITD) mutant CTT CGT ATA ATG TAT GCT ATA CG 
Vav-Cre FWD AGA TGC CAG GAC ATC AGG AAC CT 
Vav-Cre REV ATC AGC CAC ACC AGA CAC AGA GAT C 
JAK2(V617F) FWD CGT GCA TAG TGT CTG TGG AAG TC 
JAK2(V617F) REV CGT GGA GAG TCT GTA AGG CTC AA 
UBC-Cre FWD GCA TTA CCG GTC GAT GCA ACG AGT GAT GAG 
UBC-Cre REV GAG TGA ACG AAC CTG GTC GAA ATC AGT GCG 
TGFβR2fl/fl FWD TAA ACA AGG TCC GGA GCC CA 







Table S2. Primers used for real-time RT-PCR; related to STAR Methods. 
PRKDC FWD CTG TGC AAC TTC ACT AAG TCC A 
PRKDC REV CAA TCT GAG GAC GAA TTG CCT  
LIG4 FWD AGC AAA AGT GGC TTA TAC GGA TG  
LIG4 REV TGA GTC CTA CAG AAG GAT CAT GC  
ATM FWD TTG ATC TTG TGC CTT GGC TAC 
ATM REV TAT GGT GTA CGT TCC CCA TGT 
BRCA1 FWD CAG AGG ACA ATG GCT TCC ATG 
BRCA1 REV CTA CAC TGT CCA ACA CCC ACT CTC 
BRCA2 FWD TTC AAA GAG CAA GGG CTG AC 
BRCA2 REV TGG GAA CAT TCC TTC CTA AGT CT 
18SrRNA FWD GTA ACC CGT TGA ACC CCA TT 
18SrRNA REV CCA TCC AAT CGG TAG TAG CG 
 
Table S3. Primers used for quantitative PCR after ChIP; related to STAR Methods. 
BRCA1 FWD Set 1 TTA TAT GCA CCA GTC AGC ACT C 
BRCA1 REV Set 1 CCA AGT GCC CAC CAG ATT AG 
BRCA1 FWD Set 5 GCC TTG GCG TCC ATT CT 
BRCA1 REV Set 5 TCT CCC TCC ACA CTT CCC 
ATM FWD Set 1 CCA CAG CAG GAA CCA CAA TA 
ATM REV Set 1 CGA AAG AGG CGG GAC AAA 
ATM FWD Set 2 GCG TGG CTA ACG GAG AAA 
ATM REV Set 2 CTG CAC TCG GAA GGT CAA A 
BRCA2 FWD Set 4 GCG CCT CGG GTG TCT TT 
BRCA2 REV Set 4 GCT CCA GAG GTG CAG TTC TTT 
PRKDC FWD Set 1 GCA GTC TCC TGA AAC CAT CTT A 
PRKDC REV Set 1 ACT GCT CAC TTG CCA CTA TAT C 
PRKDC FWD Set 2 GTG GTG GCT CAC ACC TAT AAT C 
PRKDC REV Set 2 CAC TAT ATT GGT CAG GCT GCT ATC 
LIG4 FWD Set 1 GAG CAG ACA AAG ACG CTA GAA 





Table S4. Primers used for generation of transactivation reporters; related to STAR Methods. 
ATM FWD ACAGCT-ggtacc-CCACAGCAGGAACCACAATA  
ATM REV   ACATCG-ctcgag-CTGCACTCGGAAGGTCAAA 
BRCA1 FWD ACATCG-ctcgag- ATCCACTCTCCCACGCCAGT 
BRCA1 REV ACAGCT-ggtacc-CCAAGTGCCCACCAGATTAG 
BRCA2 FWD ACAGCT-ggtacc-CACACTGAGAAATACCCGCAG 
BRCA2 REV ACATCG-ctcgag-GCTCCAGAGGTGCAGTTCTTT 
PRKDC FWD ACATCG-ctcgag-CTGCTCAGGACGCATTCCT 
PRKDC REV ACAGCT-ggtacc-CACTATATTGGTCAGGCTGCTATC 
LIG4 FWD ACATCG-ctcgag-GAGCAGACAAAGACGCTAGAA 
LIG4 REV ACAGCT-ggtacc- GACCCTAACCAGGATCCTGC 
 
